Gemigliptin
A novel potent, selective, competitive and orally active DPP4 inhibitor with potential for the treatment of type 2 diabetes; exhibits potent anti-glycation properties in vitro and in vivo, also improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.Diabetes Approved.
Product Specifications
CAS Number
911637-19-9
Product Name Alternative
LC15-0444 | LC150444 | LC 150444
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO : ≥ 122.5 mg/mL 250.33 mM
Smiles
C1CC (CN (C1=O) CC (CC (=O) N2CCC3=C (C2) N=C (N=C3C (F) (F) F) C (F) (F) F) N) (F) F
Molecular Formula
C18H19F8N5O2
Molecular Weight
489.37
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(S) -1- (2-amino-4- (2,4-bis (trifluoromethyl) -5,8-dihydropyrido[3,4-d]pyrimidin-7 (6H) -yl) -4-oxobutyl) -5,5-difluoropiperidin-2-one
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Abhd11 sgRNA CRISPR Lentivector (Mouse) (Target 2)
3- (3-amino-2-hydroxy-propyl) -1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one
